Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the Northern District of California on behalf of shareholders of PROCEPT BioRobotics Corporation who purchased shares between February 28, 2024 and February 25, 2026.
Procept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 25, 2026, the Company announced earnings results for its fourth fiscal quarter and year ending December 31, 2025, disclosing that, contrary to prior assurances that U.S. handpiece sales were largely commensurate with procedures, handpiece sales had in fact materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units. Due to this inventory glut, the Company revealed that quarterly handpiece unit sales in the U.S. had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%, resulting in the Company widely missing its annual revenue guidance by tens of millions of dollars.
On this news, the price of Procept shares fell from $27.84 per share on February 25, 2026 to $22.69 per share on February 27, 2026, a decline of more than 18% over a two-day trading period, on above-average trading volume.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until September 22, 2026 to request that the court appoint them lead plaintiff.